Tuberous sclerosis is an autosomal dominant disorder characterized by the development of benign growths in many tissues and organs. Linkage analysis revealed two disease-determining genes on chromosome 9 and chromosome 16. The TSC2 gene on chromosome 16 encodes a 1784-amino acid tumor suppressor protein, tuberin, that functions as a GTPase-activating protein for Rap1, a member of the superfamily of Ras-related proteins. By immunoblot analyses, we found TSC2 expression to be high in G 0 as well as in early small G 1 cells. Analyses after different cell synchronization procedures revealed that TSC2 mRNA and protein expression do not fluctuate throughout the cell cycle. Using inducible expression systems we further demonstrated that TSC2 expression is not affected by overexpression of the mitogenic transcription factor E2F-1 or c-Myc. Nevertheless, antisense inhibition of tuberin expression in logarithmically growing cells markedly decreased the percentage of cells in G 1 . Furthermore, we found that cells exposed to TSC2 antisense oligonucleotides did not undergo G 0 arrest after serum withdrawal. Antisense inhibition of TSC2 expression also induced quiescent G 0 -arrested fibroblasts to reenter the cell cycle. Our data show for the first time that the absence of tuberin can both induce cells to pass through the G 1 /S transition of the eukaryotic cell cycle and prevent them from entering a quiescent state. These results have clear implications for the tumor suppressor function of TSC2. We further found that reentry into the cell cycle upon loss of TSC2 is dependent on the activity of the G 1 cyclin-dependent kinases (CDKs), Cdk2 or Cdk4. Taken together with our finding that antisense inhibition of TSC2 causes up-regulation of cyclin D1 expression, these results provide the first evidence for a connection between tuberin/Rap1 and the G 1 CDK-dependent regulation of the transition from G 0 /G 1 to S phase.
Tuberous sclerosis (TSC)
1 is an autosomal dominant condition with an estimated prevalence of about 1 in 10,000, with two-thirds of cases being sporadic (1) . Individuals affected with TSC develop characteristic skin lesions, giant cell astrocytomas, cardiac rhabdomyosarcomas, and hamartomas involving eyes, skin, kidney, and the central nervous system. Half of the patients show evidence of mental retardation (2, 3) . Linkage studies in families with TSC show that about 50% are associated with a mutant TSC2 gene, located on chromosome 16 , while an as yet unidentified gene (TSC1), which maps to chromosome 9, is implicated in the remainder (4 -8) . Mutations in the TSC2 gene have been described in patients with TSC (9, 10) , and loss of heterozygosity at the TSC2 locus has been demonstrated in TSC patient lesions as well as in sporadic tumors of non-TSC patients (11) (12) (13) . The TSC2-encoded protein, designated tuberin, contains a region of homology to the GTPase-accelerating protein (GAP) for the small molecular weight GTPase Rap1, which is a member of the superfamily of Ras-related proteins (4) . Recently, it was demonstrated that tuberin indeed stimulates the intrinsic GTPase activity of Rap1a in vitro, but not of Rap2, Ha-Ras, Rac, or Rho (14) , and that tuberin co-localizes with Rap1 in the Golgi apparatus (15) . Like other GTP-binding proteins, Rap1 is active when bound to GTP and inactive when bound to GDP; thus, by accelerating the intrinsic GTPase activity of Rap1, tuberin can inactivate it. However, the biological role of Rap1 has not yet been identified.
The Eker rat strain has provided an animal model system for the analysis of TSC2. The Eker mutation is a germline insertion in the rat homologue of the human TSC2 gene, resulting in premature truncation of TSC2 (16 -18) . Heterozygous carriers are characterized by the onset of renal tumors, sometimes associated with other neoplasia, and the susceptibility of these rats to carcinogens is increased (19, 20) . Fetuses homozygous for the Eker TSC2 mutation die in midgestation with apparent abnormalities in central nervous system development (19) . Recently, direct evidence for the tumor suppressor function of TSC2 was obtained by introduction of the TSC2 cDNA into cell lines derived from Eker rat tumors. Overexpression of TSC2 inhibited the growth and suppressed the tumorigenicity of these lines (21, 22) .
In the mammalian cell cycle, the transition from the G 0 /G 1 phase to S phase, in which DNA replication occurs, has been shown to be regulated by cyclin-dependent kinases (CDKs). During early G 1 , cyclin D-Cdk4/Cdk6 complexes operate to phosphorylate the retinoblastoma protein (pRB) and thereby activate the transcription factor E2F. Among the genes acti-vated via this mechanism are those for cyclin E and cyclin A, which when complexed with Cdk2 promote the G 1 /S transition by further phosphorylation of pRB. Finally, cyclin A-CDC2 and cyclin B-CDC2 complexes drive cells into mitosis (M phase) (23) (24) (25) .
In this study, we investigated the role of TSC2 in the regulation of the eukaryotic cell cycle. We found TSC2 mRNA and protein to be expressed in a cell cycle-independent fashion and also to be expressed at high levels in quiescent G 0 -arrested cells. By analyzing logarithmically growing Rat1 fibroblasts as well as human neuroblasts, we found that antisense inhibition of TSC2 expression markedly decreased the percentage of cells in G 1 , indicating that the length of G 1 was shortened relative to other phases of the cell cycle. Furthermore, cells exposed to TSC2 antisense oligonucleotides did not undergo G 0 arrest after serum withdrawal. Consistent with the demonstrated tumor suppressor function of TSC2, antisense inhibition of TSC2 expression in G 0 -arrested cells was found to be sufficient to induce proliferation. We further demonstrate that this induction of the G 0 /S transition is dependent on the activity of the G 1 cyclin-dependent kinases, Cdk2 and Cdk4, and that cyclin D1 expression is induced upon antisense inhibition of TSC2 expression. These findings identify tuberin as a potent cell cycle regulator and show that the G 1 CDKs functionally link tuberin to passage through the G 1 phase of the cell cycle.
MATERIALS AND METHODS
Tissue Culture-Culture conditions have previously been described in detail (26) . All cells were grown either in Dulbecco's modification of Eagle's medium or in RPMI 1640 medium, both supplemented with 10% calf serum and antibiotics (30 mg/liter penicillin, 50 mg/liter streptomycin sulfate). All cultures were kept at 37°C and 7% CO 2 and routinely screened for mycoplasma. Serum arrest was performed by cultivation of the cells for 3 days in 0.1% calf serum. Inhibition of the intracellular G 1 CDKs was performed by adding 20 M Flavopiridol (Drug Synthesis and Chemistry Branch, NCI, National Institutes of Health, Bethesda, MD) into the medium described above.
Cells-The following lines were obtained from the American Type Culture Collection: 3T6 permanent line of contact-inhibited murine fibroblasts (ATCC CCL96), Y-79 human retinoblastoma cells (ATCC HTB 18), MOLT-4 human acute lymphoblastic leukemia cells (ATCC CRL1852), HeLa human cervical carcinoma cells (ATCC CCL2), SK-N-SH human neuroblastoma cells (ATCC HB11), and IMR-32 human neuroblastoma cells (ATCC CCL127). Rat1MycER cells express a protein containing the hormone binding domain of the human estrogen receptor fused to the 3Ј-end of human Myc (27) . Growth and Myc induction was performed as described by Pusch et al. (28) . Rat1E2F cells are stably transfected with the open reading frame of human E2F-1 downstream of a mutated metallothionein promoter, which can be induced in the presence of zinc (29) . Human lymphocytes were isolated from the heparinized peripheral blood of a normal subject using the Ficoll-Hypaque gradient method and washed three times in phosphate-buffered saline. Lymphocytes were stimulated with phytohemagglutinin and analyzed after reaching logarithmic growth (26) . The TSC2-negative Ewing sarcoma cells are described in detail in Ref. 30 .
Flow Cytometry and [ 3 H]Thymidine
Incorporation-For cytofluorometric analyses, cells were harvested by trypsinization and fixed by rapid submersion in 5 ml of ice-cold 85% ethanol. After at least 1 h fixation at Ϫ20°C, cells were pelleted and stained in 1 ml of staining solution (0.25 mg/ml propidium iodide, 0.05 mg/ml RNase, 0.1% Triton X-100 in citrate buffer (pH 7.8)). Stained cells were analyzed on a Becton-Dickinson FACScan. In addition, growth rates were determined by pulse labeling with radiolabeled thymidine. Labeled DNA was precipitated by trichloracetic acid, collected on glass fiber filters, and quantitated by scintillation counting.
Centrifugal Elutriation-Separation of logarithmically growing cells into distinct cell cycle phases was accomplished by centrifugal elutriation in a Beckman J2-21 M centrifuge and a JE-6B rotor with a standard separation chamber. The rotor was kept at a speed of 2000 rpm, temperature was 20°C, and medium flow was controlled with a Cole-Parmer Masterflex pump. The elutriation medium consisted of 0.9 mM CaCl 2 , 0.5 mM MgCl 2 , and 2% calf serum in PBS. Consecutive fractions of 150 -300 ml were collected at increasing flow rates. Cytofluorometric analysis of the cell cycle distribution of each fraction was performed as described above (for further technical details see Ref. 26) .
Northern Blot Analyses-Northern blot analyses were performed as described previously (31) . RNA, prepared using TriReagent (Molecular Research Center, Inc.), was denatured in 1 M deionized glyoxal, 4.8% dimethyl sulfoxide and 10 mM sodium phosphate (pH 6.8) for 1 h at 50°C. RNA was resolved on a 1.2% agarose gel in 10 mM sodium phosphate (pH 6.8), transferred to nylon in 20 ϫ SSC, and immobilized by UV fixation. Filters were hybridized in 1% bovine serum albumin, 7% SDS, 0.5 M sodium phosphate buffer (pH 6.8), and 1 mM EDTA for at least 10 h at 65°C. After successive washing in 0.5% bovine serum albumin, 5% SDS, 40 mM sodium phosphate (pH 6.8), and 1 mM EDTA and in 1% SDS, 40 mM sodium phosphate (pH 6.8), 1 mM EDTA at 65°C, filters were exposed. Hybridization cDNA probes were specific for rat and human TSC2 and cyclin A, respectively, and a 1300-base pair fragment of the rat glyceraldehyde-3-phosphate dehydrogenase gene (16, 29) . Filters were stripped between hybridizations by incubation in 0.1 ϫ SCC, 0.1% SDS for 30 min at 95°C.
Western Blot Analyses-Protein extracts were prepared in buffer containing 20 mM HEPES, pH 7.9, 0.4 M NaCl, 2.5% glycerol, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM NaF, 0.5 mM Na 3 VO 4 , 0.02 g/ml leupeptin, 0.02 g/ml aprotinin, 0.003 g/ml benzamidine chloride, 0.1 g/ml trypsin inhibitor, and 0.5 mM dithiothreitol. After 20 min on ice, the extracts were centrifuged and supernatants were stored at Ϫ70°C. Protein concentrations were determined using the Bio-Rad protein assay reagent with bovine serum albumin as a standard. A total of 200 g of protein was run on a 8% SDS-polyacrylamide gel and transferred to nitrocellulose. Immunodetection was performed using anti-human tuberin antibodies numbers 4993, 4994, 5051, 5052, and 5063 (for preparation of antisera and affinity purification of tuberin antibodies see Refs. 14 and 15), anti-RET antibody (SC-167, Santa Cruz Biotechnology, Inc.), and anti-cyclin D1 antibody (Upstate Biotechnology, Inc.). Signals were developed using the enhanced chemiluminescence method (Amersham Corp.) (31) .
Antisense Treatment-The antisense oligonucleotides used were as follows: Gap3A, antisense oligonucleotide specific for the GAP3 region of the TSC2 gene (CGGTGCTTGTCCACGTCCTT); StartA, antisense oligonucleotide specific for the 5Ј region of the TSC2 gene (TTGCTT-GTTGGTTTGGCCAT); Gap3R (control oligonucleotide), oligonucleotide of the same length with the same proportion of the four base pairs but randomly organized (GCTTCGTTTGTCAGTGTTGT); StartS (control oligonucleotide), the corresponding sense oligonucleotide to StartA (AT-GGCCAAACCAACAAGCAA). The oligonucleotides were purchased from Pharmacia Biotech (Vienna, Austria). We used phosphorothioate oligomers (PTOs) to ensure sufficient stability against intracellular DNases. All PTOs were repeatedly ethanol-precipitated and were dissolved in double distilled water and quantitated by absorbance at A 260 . The cells were grown as described above, and the PTOs were added into freshly changed medium at different concentrations. Concentrations up to 40 M had no toxic effects on the used cells. Concentrations lower than 5 M did not lead to significant reduction of intracellular tuberin levels. We routinely used 15 M oligonucleotides, which induced significant down-regulation of tuberin without any effects on the cell viability or morphology. For a detailed description of the antisense treatment protocol used as well as a description of the specificity, biological stability, intracellular availability, gene suppression potency, toxicity, and nonspecific effects of PTOs see Ref. 32 .
DNA Transfection and Bromodeoxyuridine Incorporation-TSC2 cDNA downstream of a constitutive expression promoter and CMV/ CD20 were co-transfected into cell culture cells by the calcium phosphate method as described earlier (31) . Cells were labeled for the last 3 h of transient expression with bromodeoxyuridine (BrdUrd). CD20-positive cells were immunocytochemically detected by staining with a fluorescein isothiocyanate-conjugated anti-CD20 antibody (Becton Dickinson), and BrdUrd incorporation was visualized by incubation with a monoclonal anti-BrdUrd antibody (Sigma) and a rhodamineconjugated secondary antibody (Serotec).
RESULTS

Expression of TSC2 Is High in Quiescent Cells and Does Not
Fluctuate throughout the Cell Cycle-We investigated the expression of TSC2 mRNA and protein in different rodent and human cell lines by Northern and Western blot analyses. Although we observed clear differences in the DNA distributions of the analyzed cells, we could not detect significant variations in TSC2 expression (Table I ). In the course of these investigations, we have used different anti-tuberin antibodies in immu-TSC2 in the Cell Cyclenoblot analyses (4993, 4994, 5051, 5052, and 5063; for preparation of antisera and affinity purification of tuberin antibodies, see Refs. 14 and 15). Sera 5051 and 5052 were raised against amino acids 1165-1393 of human tuberin, while sera 4993 and 5063 were raised against amino acids 1387-1784. With the exception of the antibody 4994, raised against the N-terminal amino acids 2-305 of human tuberin, we did not see any differences in specificity and sensitivity of tuberin detection in the analyzed cells using the different antisera. The fact that the antibody 4994 does not efficiently recognize tuberin in immunoblot analyses was previously reported (14) . Only 3 of 16 analyzed cell types expressed lower TSC2 levels. Two of them were leukemia cell lines (Table I) . Interestingly, recently two other leukemia cell types of the myelocytic/monocytic lineage, HL-60 and U-937, were reported to express little or no tuberin (14) . In addition, we found a Ewing sarcoma cell line to be tuberin-negative. Whether this finding describes any functional role of TSC2 in the development of this type of neoplasia remains to be elucidated. The data presented in Table I allow two conclusions. First, there is no relation between cell cycle distribution and TSC2 expression, and second, altered TSC2 expression is not a general phenomenon of transformation. The first conclusion is further supported by the observation that unstimulated peripheral lymphocytes and phytohemagglutinin-stimulated lymphocytes express equal amounts of tuberin (Table I) .
To explore whether the mitogenic transcription factors E2F-1 or c-Myc play any role in the regulation of TSC2 expression, we used two different inducible Rat1 cell systems. In these cells the transcription factors can be activated by adding tamoxifen or zinc to the medium, respectively (27) (28) (29) . In these lines, activation induces the transcription of typical E2F-1-or c-Myc-dependent genes, such as cyclin A or cyclin E (29, 33) . However, TSC2 expression was not affected by overexpression of these transcription factors (Table I) .
To prove that TSC2 expression in cycling cells is indeed independent of the cell cycle phase, we separated logarithmically growing cells by centrifugal elutriation. The results obtained show that neither TSC2 mRNA nor protein expression fluctuate throughout the cell cycle (Fig. 1) . As a control for the experimental procedure, we co-analyzed cyclin A mRNA expression, which is well known to be induced at the G 1 /S transition ( Fig. 1 ; see Refs. 24 and 25). These data were confirmed by analyses of elutriated HeLa human cervical carcinoma cells (data not shown). Experiments in which arrested cells were restimulated with serum further revealed that TSC2 expression is high in quiescent, serum-arrested cells (Fig. 2) . The high expression in G 0 cells is in accordance with the role of tuberin as a tumor suppressor. As described above, the loss of functional TSC2 in specific differentiated quiescent cells induces proliferation, leading to the development of benign growths in many tissues and organs of tuberous sclerosis patients. 
TSC2 Function Is an Essential Component of Cell Cycle
Control-To examine the effects of down-regulating tuberin expression on cell cycle control, we employed antisense oligonucleotides to block the expression of tuberin. We used two different antisense PTOs, one directed against the GAP3 region of the TSC2 gene (Gap3A) and the other against its 5Ј start region (StartA). As mismatch control oligonucleotides, we used Gap3R, an oligonucleotide of the same length with the same proportion of the four base pairs but randomly organized, and StartS, the corresponding sense oligonucleotide to StartA. Treatment of either cycling or quiescent cells with the antisense oligonucleotides resulted in a dramatic reduction of the level of tuberin, whereas the mismatch controls had no effects on the intracellular level of tuberin (Figs. 3B and 4) . Shorter exposures of highly separated immunoblot gels frequently revealed a doublet of the tuberin band. This doublet, potentially reflecting the products of splicing variants of the TSC2 mRNA or post-translational modifications of tuberin, has been previously observed in Western blots of several rat and human tissues (15) . As shown in Fig. 3B , the antisense treatment led to a significant reduction in the intensity of all the observed tuberin bands.
Exponentially growing Rat1 and human neuroblastoma SK-N-SH cells were treated with TSC2 antisense or mismatch control PTOs and allowed to proliferate in medium containing a high concentration of serum (10%) for an additional 24 h. This treatment markedly decreased the percentage of cells in G 1 (Table II) , showing that the length of G 1 was shortened relative to other phases of the cell cycle. No effect on cell cycle distribution was seen in cells treated with the mismatch control. These results demonstrate that the amount of tuberin expressed in proliferating cells plays a role in controlling the length of G 1 phase of the cell cycle. In further experiments, a proliferating population of Rat1 cells was found to contain about 30% of the cells in S phase, and this proportion fell to about 3-5% 72 h after serum withdrawal (Table III) . Cells exposed to TSC2 mismatch control PTOs behaved identically to untreated control cells. However, cells exposed to TSC2 antisense oligonucleotides did not undergo complete G 0 /G 1 arrest after serum withdrawal; about 20% of these cells were in S phase (Table III) . Thus, reduction in the level of tuberin blocks the ability of cells to undergo G 0 /G 1 arrest. To demonstrate the specificity of the antisense oligonucleotides, we showed that enforced expression of TSC2 in antisense-treated cells restored serum responsiveness. Overexpression of TSC2 by transfection of full-length cDNA under a constitutive promoter led to high protein levels of TSC2 also in TSC2-antisense oligonucleotidetreated cells (Fig. 5A ). Rat1 cells were incubated with control and antisense PTOs and transfected with CMV/CD20 and a TSC2 expression plasmid. Cells were then serum-starved, and the percentage of cells in S phase was measured by exposure to BrdUrd. TSC2-antisense treatment decreased the percentage 
FIG. 3. Antisense inhibition of TSC2 expression induces quiescent cells to enter S phase.
Logarithmically growing Rat1 fibroblasts (high serum; 10% serum) were serum-arrested in medium containing 0.1% serum for 3 days (low serum). Serum-arrested cells were treated with 15 M antisense oligonucleotide specific for the GAP3 region of the TSC2 gene (Gap3A) and with the control oligonucleotide Gap3R. A, after a 24-h incubation with oligonucleotides, DNA distributions were analyzed on the flow cytometer. B, total cellular protein extracts of the cells presented in A were immunoblotted and probed with anti-TSC2 antibody and as a control, demonstrating equivalent amounts of protein in all lanes with anti-RET antibody.
of cells that withdrew from the cell cycle after mitogen depletion, and this was reversed by transfection with TSC2 cDNA (Fig. 5B) .
When serum-arrested Rat1 cells were restimulated with medium containing a high serum concentration (10%) for 24 h, the percentage of S phase cells increased from about 5 to 30%. Strikingly, almost the same level of S phase induction was observed when arrested cells were treated with TSC2 antisense oligonucleotides under low serum conditions (0.1%) (Fig. 3A , Table IV . After a 24-h incubation with oligonucleotides, the cells were cytofluorometrically analyzed for DNA distribution after staining DNA with propidium iodide (upper panels). Total cellular protein extracts of the cells were immunoblotted and probed with anti-TSC2 antibody and anti-cyclin D1 antibody. As a control demonstrating equivalent amounts of protein in all lanes, the blot was reprobed with anti-RET antibody.
TABLE II
Antisense inhibition of TSC2 expression shortens the G 1 phase of the ongoing cell cycle Cells, logarithmically growing in high serum, were incubated for 24 h with oligonucleotides. DNA distributions were determined by flowactivated cell analyses. Gap3A, antisense oligonucleotide specific for the GAP3 region of the TSC2 gene; StartA, antisense oligonucleotide specific for the 5Ј region of the TSC2 gene; Gap3R, control oligonucleotide of the same length with the same proportion of the four base pairs but randomly organized; StartS, the corresponding sense control oligonucleotide to StartA. (as a control, we used the empty expression vector). As a control demonstrating equivalent amounts of protein in all lanes, the blot was reprobed with anti-RET antibody. B, cycling Rat1 fibroblasts were incubated with TSC2 antisense PTOs (Gap3A) or mismatch control oligonucleotides (Gap3R). Cells were transfected with the empty plasmid or TSC2 expression vector and CMV/CD20. Cells were rinsed once with serum-free medium and incubated for 2 days in medium containing 0.1% serum (low serum). Cells were labeled for the last 3 h of the experiment with BrdUrd. Cells were immunostained for CD20 expression and BrdUrd incorporation. The percentage of CD20-positive cells that incorporated BrdUrd was determined.
oligonucleotides express low levels of tuberin and continue to proliferate for at least 40 h without mitogens before they begin to lose viability (data not shown). We have not yet determined whether these cells undergo a specific apoptotic program. These data have important implications for the tumor suppressor function of TSC2, since they show that loss of functional tuberin is sufficient to induce proliferation of quiescent cells.
The G 1 CDK Pathway Links TSC2-dependent Mitogenic Signaling to the Cell Cycle Regulation-In the mammalian cell cycle, the transition from the G 0 /G 1 phase to S phase has been shown to be regulated by the appearance of cyclin D-Cdk4 activity followed by cyclin E-Cdk2 and cyclin A-Cdk2. These kinases induce a cascade regulating the transcriptional induction of S phase-specific activities (23) (24) (25) . To explore the role of these kinases in the induction of G 0 /S transition via loss of functional tuberin, we made use of the chemical inhibitor, flavopiridol. At the concentration employed (20 M), flavopiridol inhibits the activities of Cdk1/Cdc2, Cdk2, and Cdk4 (reviewed in Ref. 34 ). We arrested Rat1 cells by incubating the cells for 72 h in 0.1% serum. Subsequent incubation of these quiescent cells for 24 h in medium containing 10% serum led to S phase reentry. This induction could be completely inhibited by adding flavopiridol to the medium (Table V) . Whereas treatment with TSC2 antisense oligonucleotides was sufficient to drive quiescent cells into S (as described above; see Table IV) , parallel incubation with flavopiridol inhibited this induction of proliferation (Table V) . To confirm that TSC2 antisense PTOs had no effects on cell cycle progression of quiescent flavopiridoltreated cells, we assayed incorporation of tritiated thymidine into nuclear DNA as an independent measure (Table V) . Since inhibition of Cdk1/Cdc2 kinase arrests cells in G 2 , not in G 1 , these data strongly support a requirement for Cdk2 or Cdk4 activities during S phase induction following reduction of TSC2 expression.
The first response upon mitogenic stimulation of quiescent cells is the induction of cyclin D proteins, which function as the regulatory subunits of Cdk4, in early G 1 (23) (24) (25) . In light of this, we examined whether inactivation of TSC2 expression affects cyclin D1 protein expression. To uncouple possible effects of loss of TSC2 on cyclin D1 expression from mitogenic effects, we analyzed logarithmically growing Rat1 cells. Antisense inhibition of tuberin in cycling Rat1 cells induced an increase in the proportion of S phase cells of approximately 10%, with a concomitant decrease in the proportion of G 1 cells (Table II, Fig. 4) . We have previously shown, using centrifugal elutriation experiments, that cyclin D1 protein is expressed from early to mid G 1 and is almost undetectable in S phase of logarithmically growing Rat1 cells. In exponentially growing Rat1 cell populations, cyclin D1 protein expression declines with increasing amounts of S phase cells (28) . Accordingly, from cell cycle distributions we would expect to detect lower amounts of cyclin D1 protein in Rat1 cells treated with TSC2 antisense oligonucleotides. Surprisingly, however, Western blot analyses revealed that cyclin D1 protein levels were significantly higher in cycling Rat1 cells treated with TSC2 antisense oligonucleotides than in cells treated with mismatch control PTOs (Fig. 4) . Cyclin D1 protein expression in untreated cells was the same as in cells treated with mismatch oligonucleotides (data not shown). Thus, reducing the level of tuberin with the antisense oligonucleotides both increased the proportion of cells in S phase and was associated with an increase in the expression of cyclin D1.
DISCUSSION
One characteristic of some tumor suppressor molecules is that their functional loss can induce quiescent (differentiated) cells to proliferate and thereby become susceptible to the transformation process (23, 35) . Therefore, tumor suppressor proteins frequently have effects on the duration of, and progression through, the mammalian cell cycle. Here we report, using antisense oligonucleotides, that reducing the expression of the TSC2 product tuberin has profound effects on the cell cycle. First, it was found that antisense inhibition of tuberin expression was sufficient to induce quiescent Rat1 fibroblasts to enter S phase. This effect was strikingly potent, since treated cells maintained the same proportion of cells in S phase as cells that were growing continuously in the presence of high serum, whereas control populations showed a 5-6-fold reduction in the proportion of cells in S phase under the experimental conditions used. These results suggest that tuberin may play a critical and direct role in the regulation of cell growth arrest at the G 0 /G 1 boundary. A second, related effect of tuberin expression revealed in these studies was that antisense inhibition of tuberin prevented cell cycle arrest in response to mitogen depletion. Thus, the treated cells continued through the cell cycle under conditions (removal of serum) where virtually all of the control cells became growth-arrested. These results suggest that cells lacking functional tuberin, such as the cells that give rise to the lesions of TSC patients, may also fail to arrest Table IV . DNA distributions were determined by flow activated cell analyses. Relative DNA replication levels were determined by pulse incorporation of radiolabeled thymidine (TdR) into the DNA. These levels are presented in percentages relative to the highest value. Gap3A, antisense oligonucleotide specific for the GAP3 region of the TSC2 gene; Gap3R, control oligonucleotide; StartA, antisense oligonucleotide specific for the 5Ј region of the TSC2 gene; StartS, the corresponding sense control oligonucleotide to StartA. Rat1 cells were grown for 72 h on 0.1% FCS, followed by 24 h of incubation with an oligonucleotide. Although we have employed antisense oligonucleotides to experimentally manipulate the levels of tuberin expression in cells, it is likely that the effects described here represent a normal role for tuberin in regulating critical aspects of the cell cycle. Such a role is consistent with the phenotype of TSC patients, who inherit one defective TSC2 allele and frequently lose the remaining normal allele in many of the hamartomas that develop in such patients (9 -13) . It is also consistent with the role of other known tumor suppressor gene products and some of the other regulators of the cell cycle. Several of these proteins have activities that are high in G 0 /G 1 cells and become down-regulated when cells leave the quiescent state to pass through the G 1 /S transition. Different mechanisms regulate these stage-dependent activities, including cell cycle-dependent synthesis and degradation. Indeed, this is how cyclins were originally identified (23) (24) (25) . However, such a mechanism does not appear to regulate tuberin, since tuberin was found to be constitutively expressed throughout the eukaryotic cell cycle. TSC2 expression does not fluctuate throughout the ongoing cell cycle either in Rat1 fibroblasts or in HeLa human cervical carcinoma cells, and tuberin is highly expressed in quiescent cells. In addition, TSC2 expression levels remain unaffected when peripheral quiescent lymphocytes are phytohemagglutinin-stimulated or when fibroblasts leave the quiescent state after serum restimulation; nor did the induction of c-Myc or E2F-1 transcription factors alter the level of tuberin expression. These results suggest that a different type of mechanism regulates the activity of tuberin during different stages of the cell cycle. One alternative possibility is suggested by mechanistic aspects of the regulation of pRB. The state of pRB phosphorylation regulates its interaction with the transcription factor E2F and thereby activates cascades necessary for the initiation of DNA replication (23, 25) . Similarly, the cell cycle function(s) of tuberin may be regulated on other levels, such as its phosphorylation or its interaction with other proteins. Detailed investigations will be necessary to further elucidate these mechanisms.
One possible mechanism that may underlie the effects of tuberin on the cell cycle was originally suggested by the presence in tuberin of a region of homology to GAP for the small molecular weight GTPase Rap1 (4). Recently, it has been shown that tuberin, like Rap1GAP, possesses in vitro GAP activity for Rap1 (14) . Rap1 is a member of the superfamily of Ras-related proteins, which are active when bound to GTP and inactive when bound to GDP (36 -38) . Thus, by accelerating the intrinsic GTPase activity of Rap1, tuberin can lead to its inactivation. Therefore, loss of TSC2, as observed in different tissues and organs of tuberous sclerosis patients, may lead to the constitutive activation of Rap1. Although its biological role has not been identified, Rap1 has been shown to induce DNA synthesis and morphological changes when microinjected in 3T3 mouse fibroblasts (39) . This suggests that like Ras, Rap1 (which is highly homologous to Ras) may have a role in regulating signaling pathways that result in DNA synthesis (38) . It has recently been shown that Ras is activated in HeLa cells, following release from a mitotic block, and in 3T3 mouse fibroblasts, following serum-stimulated cell cycle entry. In each case, peak Ras activation occurred in mid-G 1 phase (40) . In another study, inactivation of Ras in cycling cells caused a decline in cyclin D1 protein levels, accumulation of the hyperphosphorylated, growth-suppressive form of pRB, and G 1 arrest. When pRB was disrupted, cells failed to arrest in G 1 following Ras inactivation (41, 42) . These findings map the function of Ras to mid-G 1 and connect the Ras pathway with the pRB-dependent initiation of replication. If Rap1 plays a similar role, then the loss of tuberin expression might also lead to induction of cyclin D1 expression, activation of Cdk4, phosphorylation of pRB, and initiation of replication. Given this model, it is intriguing that we found that antisense inhibition of TSC2 expression can result in induced cyclin D1 protein expression and that the induction of proliferation caused by loss of TSC2 is dependent on the activity Cdk2 or Cdk4.
The results described here demonstrating that loss of TSC2 results in up-regulation of cyclin D1 expression have strong implications for the tumor suppressor function of TSC2. The CCND1 gene on chromosome 11q13 encoding cyclin D1 classifies as a protooncogene that can be overexpressed via numerous aberrations, including gene amplification, chromosomal rearrangements, proviral insertion, and other mechanisms (43) . The use of antisense oligonucleotides to inhibit tuberin expression provides a powerful tool in the further exploration of these and other related questions.
